Literature DB >> 15551372

Evaluation of clastogenic potential of the antimalarial plant Solanum nudum.

Gonzalo Alvarez1, Adriana Pabón, Jaime Carmona, Silvia Blair.   

Abstract

Compounds isolated from Solanum nudum have shown in vitro antimalarial activity against the FCB-2 strain of Plasmodium falciparum. Diosgenone (C27H40O3) the main component isolated from the hexane extract and an aqueous extract were evaluated to measure their clastogenic potential using the micronucleus test. Three concentrations (16, 32 and 64 g/kg of weight) of the aqueous extract were administered intraperitoneally into mice, (the highest concentration corresponded to 80% LD50) and diosgenone solubilized in olive oil was inoculated at the highest concentration possible (11.187 g/kg of weight). After administration of the compounds, no induction of micronucleus was observed either in polychromatic or normochromatic erythrocytes. Interestingly, a reduction of 51% in the young/mature erythrocytes ratio was seen in cells treated with aqueous extract. We conclude that neither diosgenone nor the aqueous extract have clastogenic activity, and that the aqueous extract showed some toxicity at the above mentioned concentrations. These results are significant since diosgenone could be a new therapeutic alternative for the treatment of malaria. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551372     DOI: 10.1002/ptr.1534

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  2 in total

1.  Direct Biotransformation of Dioscin into Diosgenin in Rhizome of Dioscorea zingiberensis by Penicillium dioscin.

Authors:  Jingzhou Dong; Can Lei; Dayan Lu; Ying Wang
Journal:  Indian J Microbiol       Date:  2014-11-08       Impact factor: 2.461

2.  Evaluation of the in vitro antiplasmodial, antileishmanial, and antitrypanosomal activity of medicinal plants used in saudi and yemeni traditional medicine.

Authors:  Ramzi A Mothana; Nawal M Al-Musayeib; Mohamed F Al-Ajmi; Paul Cos; Louis Maes
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-21       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.